董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Rami Elghandour | 男 | President, Chief Executive Officer and Chairman of the Board | 43 | 2331.34万美元 | 未持股 | 2022-01-31 |
| Ali Behbahani | 男 | Director | 45 | 未披露 | 未持股 | 2022-01-31 |
| Derek Yoon | 男 | Director | 47 | 未披露 | 未持股 | 2022-01-31 |
| Kavita Patel | 女 | Director | 48 | 40.94万美元 | 未持股 | 2022-01-31 |
| Lewis T. Williams | 男 | Director | 72 | 未披露 | 未持股 | 2022-01-31 |
| David Lubner | 男 | Director | 57 | 51.02万美元 | 未持股 | 2022-01-31 |
| Jill Carroll | 女 | Director | 46 | 未披露 | 未持股 | 2022-01-31 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Rami Elghandour | 男 | President, Chief Executive Officer and Chairman of the Board | 43 | 2331.34万美元 | 未持股 | 2022-01-31 |
| Lance Thibault | 男 | Interim Chief Financial Officer | 55 | 未披露 | 未持股 | 2022-01-31 |
| Christopher Heery | 男 | Chief Medical Officer | 42 | 203.19万美元 | 未持股 | 2022-01-31 |
董事简历
中英对照 | 中文 | 英文- Rami Elghandour
-
Rami Elghandour，2012年10月加入本公司，担任本公司的首席业务官；现为本公司总裁。2008年9月至2012年10月，他在Johnson & Johnson Development Corporation（JJDC）管理投资业务，领导过一些投资活动；也在一些私营公司担任过董事，其中包括本公司。另外，他领导过JJDC 投资组合发展管理方面的战略计划。2001-2006，他任职于医疗器械公司Advanced Neuromodulation Systems，领导过一些植入式神经刺激器固件的设计开发工作，该公司后来被St. Jude Medical收购。他在University of Pennsylvania获得工商管理硕士学位，在Rutgers University School of Engineering。获得电气与计算机学士学位。
Rami Elghandour has served as our President, Chief Executive Officer and Chairman of the Board of Directors since January 2021. Previously, Mr. Elghandour served in various roles at Nevro Corp., a medical device company, from October 2012 to March 2019 including President, Chief Business Officer and most recently Chief Executive Officer and as a member of the board of Nevro Corp. from May 2016 to March 2019. From September 2008 to October 2012 Mr. Elghandour managed investments for Johnson & Johnson Development Corporation JJDC, the venture investing arm of Johnson & Johnson (NYSE:JNJ), where he led several investments and served on the board of directors of a number of private companies, including Nevro's board of directors. Additionally, he led strategic initiatives in the development and management of JJDC's portfolio. From 2001 to 2006 Mr. Elghandour worked for Advanced Neuromodulation Systems, Inc. (acquired by St. Jude Medical), a medical device company, where he led firmware design and development on several implantable neurostimulators. Mr. Elghandour received an M.B.A. from the Wharton School of the University of Pennsylvania and a B.S. in Electrical and Computer Engineering from Rutgers University School of Engineering. - Rami Elghandour，2012年10月加入本公司，担任本公司的首席业务官；现为本公司总裁。2008年9月至2012年10月，他在Johnson & Johnson Development Corporation（JJDC）管理投资业务，领导过一些投资活动；也在一些私营公司担任过董事，其中包括本公司。另外，他领导过JJDC 投资组合发展管理方面的战略计划。2001-2006，他任职于医疗器械公司Advanced Neuromodulation Systems，领导过一些植入式神经刺激器固件的设计开发工作，该公司后来被St. Jude Medical收购。他在University of Pennsylvania获得工商管理硕士学位，在Rutgers University School of Engineering。获得电气与计算机学士学位。
- Rami Elghandour has served as our President, Chief Executive Officer and Chairman of the Board of Directors since January 2021. Previously, Mr. Elghandour served in various roles at Nevro Corp., a medical device company, from October 2012 to March 2019 including President, Chief Business Officer and most recently Chief Executive Officer and as a member of the board of Nevro Corp. from May 2016 to March 2019. From September 2008 to October 2012 Mr. Elghandour managed investments for Johnson & Johnson Development Corporation JJDC, the venture investing arm of Johnson & Johnson (NYSE:JNJ), where he led several investments and served on the board of directors of a number of private companies, including Nevro's board of directors. Additionally, he led strategic initiatives in the development and management of JJDC's portfolio. From 2001 to 2006 Mr. Elghandour worked for Advanced Neuromodulation Systems, Inc. (acquired by St. Jude Medical), a medical device company, where he led firmware design and development on several implantable neurostimulators. Mr. Elghandour received an M.B.A. from the Wharton School of the University of Pennsylvania and a B.S. in Electrical and Computer Engineering from Rutgers University School of Engineering.
- Ali Behbahani
-
Ali Behbahani，自2020年4月起担任Monte Rosa治疗公司董事会成员。Behbahani博士于2007年加入风险投资公司New Enterprise Associates，Inc.，是医疗保健部门的合伙人和联席主管。在加入New Enterprise Associates，Inc.之前，Behbahani博士曾于1998年至2000年在制药公司The Medicines Company担任业务发展顾问，在跨国投资银行和金融服务公司摩根士丹利担任风险投资助理，在全球金融服务公司雷曼兄弟担任医疗保健投资银行分析师。Behbahani博士担任生物技术公司Nkarta, Inc.的董事会成员，自2015年8月起，生物制药公司Black Diamond Therapeutics, Inc.，生物制药公司，自2018年12月起，生物制药公司Adaptimmune治疗 PLC，自2014年9月起，生物技术公司CRISPR Therapeutics AG，自2015年3月起，生物技术公司Korro Bio，Inc.，自2019年8月起，生物技术公司Arcellx, Inc.，自2015年2月起。Behbahani博士曾于2013年7月至2024年9月担任医疗器械公司CVRx, Inc.的董事会成员，全球医疗器械公司Nevro Corp.，2014年8月至2019年3月，生物制药公司Oyster Point Pharma, Inc.，2017年7月至2023年1月，生物制药公司Genocea Biosciences, Inc.，2018年2月至2022年5月，生物技术公司Minerva Surgical，2011年5月至2024年1月，以及生物技术公司TERM4，Inc.至2017年。Behbahani博士获得了宾夕法尼亚大学医学院的医学博士学位、宾夕法尼亚大学沃顿商学院的工商管理硕士学位以及杜克大学的生物医学工程、电气工程和化学学士学位。
Ali Behbahani,has been a member of Monte Rosa Therapeutics, Inc. board of directors since April 2020. Dr. Behbahani joined New Enterprise Associates, Inc., a venture capital firm, in 2007 and is a Partner and Co-Head of Healthcare. Prior to joining New Enterprise Associates, Inc., Dr. Behbahani served as a consultant in business development at The Medicines Company, a pharmaceutical company, a Venture Associate at Morgan Stanley, a multinational investment bank and financial services company, and a Healthcare Investment Banking Analyst at Lehman Brothers, a global financial services firm, from 1998 to 2000. Dr. Behbahani serves as a member of the board of directors of Nkarta, Inc., a biotechnology company, since August 2015, Black Diamond Therapeutics, Inc., a biopharmaceutical company, since December 2018, Adaptimmune Therapeutics plc, a biopharmaceutical company, since September 2014, CRISPR Therapeutics AG, a biotechnology company, since March 2015, Korro Bio, Inc., a biotechnology company, since August 2019, and Arcellx, Inc., a biotechnology company, since February 2015. Dr. Behbahani formerly served as a member of the board of directors of CVRx, Inc., a medical device company, from July 2013 to September 2024, Nevro Corp., a global medical device company, from August 2014 to March 2019, Oyster Point Pharma, Inc., a biopharmaceutical company, from July 2017 to January 2023, Genocea Biosciences, Inc., a biopharmaceutical company, from February 2018 to May 2022, Minerva Surgical Inc., a biotechnology company, from May 2011 to January 2024, and Marker Therapeutics, Inc. until 2017. Dr. Behbahani received an M.D. from the University of Pennsylvania School of Medicine, an M.B.A. from the Wharton School of the University of Pennsylvania and a B.S. in biomedical engineering, electrical engineering and chemistry from Duke University. - Ali Behbahani，自2020年4月起担任Monte Rosa治疗公司董事会成员。Behbahani博士于2007年加入风险投资公司New Enterprise Associates，Inc.，是医疗保健部门的合伙人和联席主管。在加入New Enterprise Associates，Inc.之前，Behbahani博士曾于1998年至2000年在制药公司The Medicines Company担任业务发展顾问，在跨国投资银行和金融服务公司摩根士丹利担任风险投资助理，在全球金融服务公司雷曼兄弟担任医疗保健投资银行分析师。Behbahani博士担任生物技术公司Nkarta, Inc.的董事会成员，自2015年8月起，生物制药公司Black Diamond Therapeutics, Inc.，生物制药公司，自2018年12月起，生物制药公司Adaptimmune治疗 PLC，自2014年9月起，生物技术公司CRISPR Therapeutics AG，自2015年3月起，生物技术公司Korro Bio，Inc.，自2019年8月起，生物技术公司Arcellx, Inc.，自2015年2月起。Behbahani博士曾于2013年7月至2024年9月担任医疗器械公司CVRx, Inc.的董事会成员，全球医疗器械公司Nevro Corp.，2014年8月至2019年3月，生物制药公司Oyster Point Pharma, Inc.，2017年7月至2023年1月，生物制药公司Genocea Biosciences, Inc.，2018年2月至2022年5月，生物技术公司Minerva Surgical，2011年5月至2024年1月，以及生物技术公司TERM4，Inc.至2017年。Behbahani博士获得了宾夕法尼亚大学医学院的医学博士学位、宾夕法尼亚大学沃顿商学院的工商管理硕士学位以及杜克大学的生物医学工程、电气工程和化学学士学位。
- Ali Behbahani,has been a member of Monte Rosa Therapeutics, Inc. board of directors since April 2020. Dr. Behbahani joined New Enterprise Associates, Inc., a venture capital firm, in 2007 and is a Partner and Co-Head of Healthcare. Prior to joining New Enterprise Associates, Inc., Dr. Behbahani served as a consultant in business development at The Medicines Company, a pharmaceutical company, a Venture Associate at Morgan Stanley, a multinational investment bank and financial services company, and a Healthcare Investment Banking Analyst at Lehman Brothers, a global financial services firm, from 1998 to 2000. Dr. Behbahani serves as a member of the board of directors of Nkarta, Inc., a biotechnology company, since August 2015, Black Diamond Therapeutics, Inc., a biopharmaceutical company, since December 2018, Adaptimmune Therapeutics plc, a biopharmaceutical company, since September 2014, CRISPR Therapeutics AG, a biotechnology company, since March 2015, Korro Bio, Inc., a biotechnology company, since August 2019, and Arcellx, Inc., a biotechnology company, since February 2015. Dr. Behbahani formerly served as a member of the board of directors of CVRx, Inc., a medical device company, from July 2013 to September 2024, Nevro Corp., a global medical device company, from August 2014 to March 2019, Oyster Point Pharma, Inc., a biopharmaceutical company, from July 2017 to January 2023, Genocea Biosciences, Inc., a biopharmaceutical company, from February 2018 to May 2022, Minerva Surgical Inc., a biotechnology company, from May 2011 to January 2024, and Marker Therapeutics, Inc. until 2017. Dr. Behbahani received an M.D. from the University of Pennsylvania School of Medicine, an M.B.A. from the Wharton School of the University of Pennsylvania and a B.S. in biomedical engineering, electrical engineering and chemistry from Duke University.
- Derek Yoon
-
Derek Yoon，他曾一直担任我们公司的董事（2015年12月以来）。他曾担任AJU IB Investment公司（风险投资公司总部设在韩国首尔）的马萨诸塞州波士顿办公室的合伙人（2014年1月以来）。此前，他曾担任RBS Citizens Bank的投资组合经理，负责医疗银行苏格兰皇家银行国民银行（从2011年4月到2013年12月）。2009年7月至2011年5月，他曾担任Berwind Private Equity公司的研究副合伙人。此前，他曾担任投资银行行业的多种职务。他持有Yonsei University Seoul（位于韩国）的化学工程学士学位，以及Babson College的工商管理硕士学位、Boston College的林学硕士学位。
Derek Yoon has served as a member of our board of directors since April 2020. Mr. Yoon has been employed as President & CEO at Solasta Ventures previously known as Aju IB Investment (Solasta), a venture capital firm, since November 2013 and a member of the board of directors of Solasta since July 2019. Since December 2017 Mr. Yoon has served as member of the board of directors of Trefoil Therapeutics, and between December 2015 and August 2017 Mr. Yoon served on the board of directors of Clearside Biomedical (Nasdaq:CLSD). Prior to Solasta, Mr. Yoon was a Portfolio Manager with RBS Citizens from April 2011 to November 2013. From July 2009 to April 2011 Mr. Yoon was an Investment Manager at Berwind Private Equity. From October 1999 to July 2007 Mr. Yoon was Investment Manager at Kibo Capital in South Korea. Mr. Yoon received a Master of Finance from Boston College and a M.B.A. from Babson College. Mr. Yoon also received a B.S. in Chemical Engineering from Yonsei University in South Korea. - Derek Yoon，他曾一直担任我们公司的董事（2015年12月以来）。他曾担任AJU IB Investment公司（风险投资公司总部设在韩国首尔）的马萨诸塞州波士顿办公室的合伙人（2014年1月以来）。此前，他曾担任RBS Citizens Bank的投资组合经理，负责医疗银行苏格兰皇家银行国民银行（从2011年4月到2013年12月）。2009年7月至2011年5月，他曾担任Berwind Private Equity公司的研究副合伙人。此前，他曾担任投资银行行业的多种职务。他持有Yonsei University Seoul（位于韩国）的化学工程学士学位，以及Babson College的工商管理硕士学位、Boston College的林学硕士学位。
- Derek Yoon has served as a member of our board of directors since April 2020. Mr. Yoon has been employed as President & CEO at Solasta Ventures previously known as Aju IB Investment (Solasta), a venture capital firm, since November 2013 and a member of the board of directors of Solasta since July 2019. Since December 2017 Mr. Yoon has served as member of the board of directors of Trefoil Therapeutics, and between December 2015 and August 2017 Mr. Yoon served on the board of directors of Clearside Biomedical (Nasdaq:CLSD). Prior to Solasta, Mr. Yoon was a Portfolio Manager with RBS Citizens from April 2011 to November 2013. From July 2009 to April 2011 Mr. Yoon was an Investment Manager at Berwind Private Equity. From October 1999 to July 2007 Mr. Yoon was Investment Manager at Kibo Capital in South Korea. Mr. Yoon received a Master of Finance from Boston College and a M.B.A. from Babson College. Mr. Yoon also received a B.S. in Chemical Engineering from Yonsei University in South Korea.
- Kavita Patel
-
Kavita Patel自2020年以来一直担任我们的董事会成员。Kavita Patel博士是华盛顿特区的执业医师，也是布鲁金斯学会（Brookings Institution）的非居民研究员，在那里她的研究和报告专注于以患者为中心的护理，支付和交付系统以及医疗改革。她此前曾任职奥巴马政府，担任白宫政府间事务和公众参与办公室的政策主管。她还曾担任已故参议员Edward Kennedy的政策分析师和助手。作为卫生部副部长，她是肯尼迪参议员领导下的卫生、教育、劳工和养老金帮助委员会的高级职员的一部分。Patel博士还担任布鲁金斯学会卫生政策中心临床转化的常务董事和约翰霍普金斯卫生系统付款人和提供者战略的Vice President。Patel博士目前在SelectQuote，Inc.公司董事会任职。Patel博士在几个非营利组织的董事会任职，包括Dignity梦百合和SSM梦百合。她在德克萨斯大学健康科学中心获得医学博士学位，在加州大学洛杉矶分校获得医学硕士学位。
Kavita Patel,was appointed to serve as a director of the Company in September 2020. Dr. Patel is a Professor of Medicine at Stanford University and a practicing primary care physician at Mary's Center in Washington, D.C. Dr. Patel has also served as a Venture Partner at New Enterprise Associates since 2017. From 2011–2021, she was a managing director of health care delivery and transformation at the Brookings Institution. Previously, Dr. Patel served as Director of Policy for the Office of Intergovernmental Affairs and Public Engagement in the White House from 2009 to 2010, as Deputy Staff Director on Health on the late Senator Edward Kennedy's staff from 2007 to 2009, and as a member of senior staff of the Senate Health, Education, Labor and Pensions Committee. Dr. Patel has served as a director and member of the Compensation Committee of Arcellx, Inc. (NASDAQ: ACLX) since December 2021. She previously served as a director and member of the Compensation Committee of Sigilon Therapeutics, Inc. (NASDAQ: SGTX) from April 2020 until its sale to Eli Lilly and Company in August 2023; as a director and member of the Governance and Nominating Committee of Tesaro, Inc. (NASDAQ: TSRO) from 2016 until its acquisition by GlaxoSmithKline in 2019; and as a director, member of the Compensation Committee, and Chair of the Nominating and Corporate Governance Committee of Intelligent Medicine Acquisition Corp (NASDAQ: IQMD) from November 2021 to April 2023. Dr. Patel received her undergraduate degree from the University of Texas at Austin, her Master of Public Health from the University of California at Los Angeles, and her medical degree from the University of Texas Health Science Center. - Kavita Patel自2020年以来一直担任我们的董事会成员。Kavita Patel博士是华盛顿特区的执业医师，也是布鲁金斯学会（Brookings Institution）的非居民研究员，在那里她的研究和报告专注于以患者为中心的护理，支付和交付系统以及医疗改革。她此前曾任职奥巴马政府，担任白宫政府间事务和公众参与办公室的政策主管。她还曾担任已故参议员Edward Kennedy的政策分析师和助手。作为卫生部副部长，她是肯尼迪参议员领导下的卫生、教育、劳工和养老金帮助委员会的高级职员的一部分。Patel博士还担任布鲁金斯学会卫生政策中心临床转化的常务董事和约翰霍普金斯卫生系统付款人和提供者战略的Vice President。Patel博士目前在SelectQuote，Inc.公司董事会任职。Patel博士在几个非营利组织的董事会任职，包括Dignity梦百合和SSM梦百合。她在德克萨斯大学健康科学中心获得医学博士学位，在加州大学洛杉矶分校获得医学硕士学位。
- Kavita Patel,was appointed to serve as a director of the Company in September 2020. Dr. Patel is a Professor of Medicine at Stanford University and a practicing primary care physician at Mary's Center in Washington, D.C. Dr. Patel has also served as a Venture Partner at New Enterprise Associates since 2017. From 2011–2021, she was a managing director of health care delivery and transformation at the Brookings Institution. Previously, Dr. Patel served as Director of Policy for the Office of Intergovernmental Affairs and Public Engagement in the White House from 2009 to 2010, as Deputy Staff Director on Health on the late Senator Edward Kennedy's staff from 2007 to 2009, and as a member of senior staff of the Senate Health, Education, Labor and Pensions Committee. Dr. Patel has served as a director and member of the Compensation Committee of Arcellx, Inc. (NASDAQ: ACLX) since December 2021. She previously served as a director and member of the Compensation Committee of Sigilon Therapeutics, Inc. (NASDAQ: SGTX) from April 2020 until its sale to Eli Lilly and Company in August 2023; as a director and member of the Governance and Nominating Committee of Tesaro, Inc. (NASDAQ: TSRO) from 2016 until its acquisition by GlaxoSmithKline in 2019; and as a director, member of the Compensation Committee, and Chair of the Nominating and Corporate Governance Committee of Intelligent Medicine Acquisition Corp (NASDAQ: IQMD) from November 2021 to April 2023. Dr. Patel received her undergraduate degree from the University of Texas at Austin, her Master of Public Health from the University of California at Los Angeles, and her medical degree from the University of Texas Health Science Center.
- Lewis T. Williams
-
LewisT.Williams自2017年6月起担任董事会成员。他自2019年2月起担任生物技术初创公司Walking Fish Therapeutics的董事长兼首席执行官。Williams博士自2018年10月起还担任专注于梦百合的风险投资公司Quan Capital，LLP的风险合伙人。Williams博士于2002年1月至2020年1月创立上市生物技术公司Five PrimeTherapeutics，Inc.并担任其董事，并于2011年4月至2017年12月担任其总裁兼首席执行官。此前，Williams博士在Chiron Corporation“Chiron”（一家生物制药公司，现称为Novartis Vaccines and Diagnostics，Inc.）任职七年，最近担任其首席科学官。他也曾任职Chiron公司的董事会（1999年至2001年）。在加入Chiron之前，Williams博士是加州大学旧金山分校（University of California，San Francisco）的医学教授，并担任该大学心血管研究机构和第一研究中心的主任。Williams博士还曾在哈佛医学院（Harvard Medical School）和马萨诸塞州总医院（Massachusetts General Hospital）的院系任职，并联合创立了COR Therapeutics，Inc.，这是一家专注于心血管疾病的生物技术公司。他是美国国家科学院（National Academy of Sciences）的成员，以及美国艺术与科学院（American Academy of Arts and Sciences）的院士。Williams博士自2019年9月起担任公共生物制药公司Neoleukin Pharmaceuticals的董事会成员。他之前是COR Therapeutics，Inc.和BeckmanCoulter，Inc.的董事会成员，这两家公司在他担任董事期间都是一家上市公司。Williams博士目前还在一家私人控股公司的董事会任职。他在莱斯大学（Rice University）获得学士学位，在杜克大学（Duke University）获得医学博士学位和博士学位。
Lewis T. Williams has served as a member of our board of directors since August 2019. Dr. Williams is currently President and CEO of a private cell therapy company, Walking Fish Therapeutics, and has been venture partner at Quan Capital, a life sciences venture fund, since August 2018. Dr. Williams founded Five Prime Therapeutics Nasdaq:FPRX, a biotechnology company, in December 2001 served as Five Prime's Executive Chairman from July 2003 to January 2012 and January 2018 to December 2018 as President and Chief Executive Officer from August 2011 to December 2017 and as a member of Five Prime's board of directors from January 2002 until December 2019. Previously, Dr. Williams spent seven years at Chiron Corporation, a biopharmaceutical company, now Novartis Vaccines and Diagnostics, Inc., most recently as its Chief Scientific Officer. Prior to joining Chiron, Dr. Williams was a professor of medicine at the University of California, San Francisco and served as Director of the University Cardiovascular Research Institution and Daiichi Research Center. Dr. Williams has also served on the faculties of Harvard Medical School and Massachusetts General Hospital and co-founded COR Therapeutics, Inc., a biotechnology company focused on cardiovascular disease. He is a member of the National Academy of Sciences and a fellow of the American Academy of Arts and Sciences. Dr. Williams is currently on the board of directors of Protagonist Therapeutics, Inc. (Nasdaq:PTGX) and Neoleukin Therapeutics (Nasdaq:NLTX) and was previously a member of the board of directors of Chiron, COR Therapeutics and Beckman Coulter, Inc., each of which was a public company during his service as a director. Dr. Williams received a B.S. from Rice University and an M.D. and a Ph.D. from Duke University. - LewisT.Williams自2017年6月起担任董事会成员。他自2019年2月起担任生物技术初创公司Walking Fish Therapeutics的董事长兼首席执行官。Williams博士自2018年10月起还担任专注于梦百合的风险投资公司Quan Capital，LLP的风险合伙人。Williams博士于2002年1月至2020年1月创立上市生物技术公司Five PrimeTherapeutics，Inc.并担任其董事，并于2011年4月至2017年12月担任其总裁兼首席执行官。此前，Williams博士在Chiron Corporation“Chiron”（一家生物制药公司，现称为Novartis Vaccines and Diagnostics，Inc.）任职七年，最近担任其首席科学官。他也曾任职Chiron公司的董事会（1999年至2001年）。在加入Chiron之前，Williams博士是加州大学旧金山分校（University of California，San Francisco）的医学教授，并担任该大学心血管研究机构和第一研究中心的主任。Williams博士还曾在哈佛医学院（Harvard Medical School）和马萨诸塞州总医院（Massachusetts General Hospital）的院系任职，并联合创立了COR Therapeutics，Inc.，这是一家专注于心血管疾病的生物技术公司。他是美国国家科学院（National Academy of Sciences）的成员，以及美国艺术与科学院（American Academy of Arts and Sciences）的院士。Williams博士自2019年9月起担任公共生物制药公司Neoleukin Pharmaceuticals的董事会成员。他之前是COR Therapeutics，Inc.和BeckmanCoulter，Inc.的董事会成员，这两家公司在他担任董事期间都是一家上市公司。Williams博士目前还在一家私人控股公司的董事会任职。他在莱斯大学（Rice University）获得学士学位，在杜克大学（Duke University）获得医学博士学位和博士学位。
- Lewis T. Williams has served as a member of our board of directors since August 2019. Dr. Williams is currently President and CEO of a private cell therapy company, Walking Fish Therapeutics, and has been venture partner at Quan Capital, a life sciences venture fund, since August 2018. Dr. Williams founded Five Prime Therapeutics Nasdaq:FPRX, a biotechnology company, in December 2001 served as Five Prime's Executive Chairman from July 2003 to January 2012 and January 2018 to December 2018 as President and Chief Executive Officer from August 2011 to December 2017 and as a member of Five Prime's board of directors from January 2002 until December 2019. Previously, Dr. Williams spent seven years at Chiron Corporation, a biopharmaceutical company, now Novartis Vaccines and Diagnostics, Inc., most recently as its Chief Scientific Officer. Prior to joining Chiron, Dr. Williams was a professor of medicine at the University of California, San Francisco and served as Director of the University Cardiovascular Research Institution and Daiichi Research Center. Dr. Williams has also served on the faculties of Harvard Medical School and Massachusetts General Hospital and co-founded COR Therapeutics, Inc., a biotechnology company focused on cardiovascular disease. He is a member of the National Academy of Sciences and a fellow of the American Academy of Arts and Sciences. Dr. Williams is currently on the board of directors of Protagonist Therapeutics, Inc. (Nasdaq:PTGX) and Neoleukin Therapeutics (Nasdaq:NLTX) and was previously a member of the board of directors of Chiron, COR Therapeutics and Beckman Coulter, Inc., each of which was a public company during his service as a director. Dr. Williams received a B.S. from Rice University and an M.D. and a Ph.D. from Duke University.
- David Lubner
-
David Lubner，2010年10月起，他担任Arcellx, Inc.高级副总裁和首席财务官，2006年公司成立至2010年10月，担任兼职高级副总裁和首席运营官。2006至2010年10月，他还担任风险投资公司Mediphase Venture Partners的首席财务官。1999至2005年被IMS Health收购，他担任PharMetrics, Inc.的副总裁和首席财务官，该公司是制药和医学索赔数据信息公司。加入PharMetrics之前，1996至1999年，他担任生物制药公司ProScript, Inc.的副总裁和首席财务官。他是美国注册会计师协会（American Institute of CPAs）的成员。他在东北大学（Northeastern University）获得工商管理学士学位，在本特利大学（Bentley University）获得税收硕士学位。
David Lubner,has served as a member of Cargo Therapeutics, Inc. board of directors since July 2023. From January 2016 until June 2020, Mr. Lubner served as Executive Vice President and Chief Financial Officer of Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, acquired by UCB S.A. in April 2020. Prior to joining Ra Pharmaceuticals, Mr. Lubner served as Chief Financial Officer of Tetraphase Pharmaceuticals, Inc., a biotechnology company, from 2006 through 2016, and as Chief Financial Officer of PharMetrics Inc., a patient-based pharmacy and medical claims data informatics company, from 1999 until 2006. Prior to joining PharMetrics, Mr. Lubner served as Vice President and Chief Financial Officer of ProScript, Inc. from 1996 to 1999. Mr. Lubner currently serves on the board of directors of a number of publicly traded biotechnology companies, including Arcellx, Inc., Dyne Therapeutics, Inc., POINT Biopharma, Inc. and Vor Biopharma, Inc. He was previously a member of the board of directors of Gemini Therapeutics, Inc., which merged with Disc Medicine, Inc. in December 2022, Nightstar Therapeutics plc, which was acquired by Biogen Inc. in June 2019, and Therapeutics Acquisition Corp., a blank check company focused on the healthcare industry, sponsored by RA Capital, Boston, MA. Mr. Lubner is a Certified Public Accountant in the Commonwealth of Massachusetts. Mr. Lubner received his B.S. in Business Administration from Northeastern University and M.S. in Taxation from Bentley University. - David Lubner，2010年10月起，他担任Arcellx, Inc.高级副总裁和首席财务官，2006年公司成立至2010年10月，担任兼职高级副总裁和首席运营官。2006至2010年10月，他还担任风险投资公司Mediphase Venture Partners的首席财务官。1999至2005年被IMS Health收购，他担任PharMetrics, Inc.的副总裁和首席财务官，该公司是制药和医学索赔数据信息公司。加入PharMetrics之前，1996至1999年，他担任生物制药公司ProScript, Inc.的副总裁和首席财务官。他是美国注册会计师协会（American Institute of CPAs）的成员。他在东北大学（Northeastern University）获得工商管理学士学位，在本特利大学（Bentley University）获得税收硕士学位。
- David Lubner,has served as a member of Cargo Therapeutics, Inc. board of directors since July 2023. From January 2016 until June 2020, Mr. Lubner served as Executive Vice President and Chief Financial Officer of Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, acquired by UCB S.A. in April 2020. Prior to joining Ra Pharmaceuticals, Mr. Lubner served as Chief Financial Officer of Tetraphase Pharmaceuticals, Inc., a biotechnology company, from 2006 through 2016, and as Chief Financial Officer of PharMetrics Inc., a patient-based pharmacy and medical claims data informatics company, from 1999 until 2006. Prior to joining PharMetrics, Mr. Lubner served as Vice President and Chief Financial Officer of ProScript, Inc. from 1996 to 1999. Mr. Lubner currently serves on the board of directors of a number of publicly traded biotechnology companies, including Arcellx, Inc., Dyne Therapeutics, Inc., POINT Biopharma, Inc. and Vor Biopharma, Inc. He was previously a member of the board of directors of Gemini Therapeutics, Inc., which merged with Disc Medicine, Inc. in December 2022, Nightstar Therapeutics plc, which was acquired by Biogen Inc. in June 2019, and Therapeutics Acquisition Corp., a blank check company focused on the healthcare industry, sponsored by RA Capital, Boston, MA. Mr. Lubner is a Certified Public Accountant in the Commonwealth of Massachusetts. Mr. Lubner received his B.S. in Business Administration from Northeastern University and M.S. in Taxation from Bentley University.
- Jill Carroll
-
Jill Carroll，2013年4月以来，她一直担任公司的董事会的成员。她曾一直担任S.R.One, Limited公司（GlaxoSmithKline公司的企业风险资本分公司）的高级职务（2011年9月以来）。任职S.R.One, Limited公司之前，她曾担任Dynavax Technologies Corporation（生物制药公司）的负责公司发展的高级主管（从2004年5月到2010年8月）、Limerick Biopharma公司（制药公司）的公司发展副总裁（从2010年8月到2011年9月）。她也曾担任Clearview Projects公司（咨询公司）（从2001年10月到2004年5月）和Mercer Management Consulting公司（从1999年3月到2001年7月）的顾问。她持有杜克大学（Duke University）的化学学士学位，以及约翰·霍普金斯大学（Johns Hopkins University）的生物化学、细胞和分子生物学硕士学位。
Jill Carroll has served as a member of company's board of directors since September 2017. Ms. Carroll has served as partner of SR One Capital Management, LP S.R. One, an entity affiliated with SR One Capital Fund I Aggregator, LP since September 2020. Prior to S.R. One, Ms. Carroll was principal at S.R. One, Limited, initially joining as a Senior Associate in September 2011. From August 2010 to August 2011 Ms. Carroll served as a VP, Corporate Development at Limerick Biopharma. Between May 2004 and August 2010 Ms. Carroll was served as the Senior Director, Strategic Planning & Corporate Development at Dynavax Technologies (Nasdaq:DVAX), where she was involved in multiple pharma-partnering deals, as well as substantial private and public financings. Ms. Carroll also served as a director at Clearview Projects from Sept 2001 to May 2004 and as a consultant specializing in health care at Mercer Management Consulting from March 1999 to July 2001. Ms. Carroll is a member of the board of directors of HotSpot Therapeutics and Odyssey Therapeutics. Ms. Carroll received her B.S. in Chemistry from Duke University and her M.S. in Biochemistry, Cellular and Molecular Biology from Johns Hopkins University. - Jill Carroll，2013年4月以来，她一直担任公司的董事会的成员。她曾一直担任S.R.One, Limited公司（GlaxoSmithKline公司的企业风险资本分公司）的高级职务（2011年9月以来）。任职S.R.One, Limited公司之前，她曾担任Dynavax Technologies Corporation（生物制药公司）的负责公司发展的高级主管（从2004年5月到2010年8月）、Limerick Biopharma公司（制药公司）的公司发展副总裁（从2010年8月到2011年9月）。她也曾担任Clearview Projects公司（咨询公司）（从2001年10月到2004年5月）和Mercer Management Consulting公司（从1999年3月到2001年7月）的顾问。她持有杜克大学（Duke University）的化学学士学位，以及约翰·霍普金斯大学（Johns Hopkins University）的生物化学、细胞和分子生物学硕士学位。
- Jill Carroll has served as a member of company's board of directors since September 2017. Ms. Carroll has served as partner of SR One Capital Management, LP S.R. One, an entity affiliated with SR One Capital Fund I Aggregator, LP since September 2020. Prior to S.R. One, Ms. Carroll was principal at S.R. One, Limited, initially joining as a Senior Associate in September 2011. From August 2010 to August 2011 Ms. Carroll served as a VP, Corporate Development at Limerick Biopharma. Between May 2004 and August 2010 Ms. Carroll was served as the Senior Director, Strategic Planning & Corporate Development at Dynavax Technologies (Nasdaq:DVAX), where she was involved in multiple pharma-partnering deals, as well as substantial private and public financings. Ms. Carroll also served as a director at Clearview Projects from Sept 2001 to May 2004 and as a consultant specializing in health care at Mercer Management Consulting from March 1999 to July 2001. Ms. Carroll is a member of the board of directors of HotSpot Therapeutics and Odyssey Therapeutics. Ms. Carroll received her B.S. in Chemistry from Duke University and her M.S. in Biochemistry, Cellular and Molecular Biology from Johns Hopkins University.
高管简历
中英对照 | 中文 | 英文- Rami Elghandour
Rami Elghandour，2012年10月加入本公司，担任本公司的首席业务官；现为本公司总裁。2008年9月至2012年10月，他在Johnson & Johnson Development Corporation（JJDC）管理投资业务，领导过一些投资活动；也在一些私营公司担任过董事，其中包括本公司。另外，他领导过JJDC 投资组合发展管理方面的战略计划。2001-2006，他任职于医疗器械公司Advanced Neuromodulation Systems，领导过一些植入式神经刺激器固件的设计开发工作，该公司后来被St. Jude Medical收购。他在University of Pennsylvania获得工商管理硕士学位，在Rutgers University School of Engineering。获得电气与计算机学士学位。
Rami Elghandour has served as our President, Chief Executive Officer and Chairman of the Board of Directors since January 2021. Previously, Mr. Elghandour served in various roles at Nevro Corp., a medical device company, from October 2012 to March 2019 including President, Chief Business Officer and most recently Chief Executive Officer and as a member of the board of Nevro Corp. from May 2016 to March 2019. From September 2008 to October 2012 Mr. Elghandour managed investments for Johnson & Johnson Development Corporation JJDC, the venture investing arm of Johnson & Johnson (NYSE:JNJ), where he led several investments and served on the board of directors of a number of private companies, including Nevro's board of directors. Additionally, he led strategic initiatives in the development and management of JJDC's portfolio. From 2001 to 2006 Mr. Elghandour worked for Advanced Neuromodulation Systems, Inc. (acquired by St. Jude Medical), a medical device company, where he led firmware design and development on several implantable neurostimulators. Mr. Elghandour received an M.B.A. from the Wharton School of the University of Pennsylvania and a B.S. in Electrical and Computer Engineering from Rutgers University School of Engineering.- Rami Elghandour，2012年10月加入本公司，担任本公司的首席业务官；现为本公司总裁。2008年9月至2012年10月，他在Johnson & Johnson Development Corporation（JJDC）管理投资业务，领导过一些投资活动；也在一些私营公司担任过董事，其中包括本公司。另外，他领导过JJDC 投资组合发展管理方面的战略计划。2001-2006，他任职于医疗器械公司Advanced Neuromodulation Systems，领导过一些植入式神经刺激器固件的设计开发工作，该公司后来被St. Jude Medical收购。他在University of Pennsylvania获得工商管理硕士学位，在Rutgers University School of Engineering。获得电气与计算机学士学位。
- Rami Elghandour has served as our President, Chief Executive Officer and Chairman of the Board of Directors since January 2021. Previously, Mr. Elghandour served in various roles at Nevro Corp., a medical device company, from October 2012 to March 2019 including President, Chief Business Officer and most recently Chief Executive Officer and as a member of the board of Nevro Corp. from May 2016 to March 2019. From September 2008 to October 2012 Mr. Elghandour managed investments for Johnson & Johnson Development Corporation JJDC, the venture investing arm of Johnson & Johnson (NYSE:JNJ), where he led several investments and served on the board of directors of a number of private companies, including Nevro's board of directors. Additionally, he led strategic initiatives in the development and management of JJDC's portfolio. From 2001 to 2006 Mr. Elghandour worked for Advanced Neuromodulation Systems, Inc. (acquired by St. Jude Medical), a medical device company, where he led firmware design and development on several implantable neurostimulators. Mr. Elghandour received an M.B.A. from the Wharton School of the University of Pennsylvania and a B.S. in Electrical and Computer Engineering from Rutgers University School of Engineering.
- Lance Thibault
Lance Thibault，自2015年4月起担任主要财务官兼临时首席财务官，并担任Danforth Advisors, LLC的一个顾问职位；2010年起担任独立顾问；目前是Paratek Pharmaceuticals, Inc.（纳斯达克： PRTK）的财务董事，并且为位于大波斯顿的多家私营制药公司提供运营、财务、战略支持服务。此前，他是deCODE genetics, Inc. （纳斯达克： DCGN）的首席财务官兼财务主管，在PricewaterhouseCoopers LLP担任过多个职位。他获得了Bentley University的会计学学士学位。
Lance Thibault has served as our Interim Chief Financial Officer since January 2022. Since January 2014 Mr. Thibault has served as managing director of Danforth Advisors, LLC providing operational, financial and strategic services at a number of private and public pharmaceutical and biotechnology companies, including as Interim Chief Financial Officer of Aadi Bioscience, Inc. NASDAQ: AADI from July 2021 to November 2021 as Acting Chief Financial Officer of Pieris Pharmaceuticals, Inc (NASDAQ: PIRS) from February 2017 to April 2018 and as Interim Chief Financial Officer of Proteostasis Therapeutics, Inc. (NASDAQ: PTI) from April 2015 to August 2016. Prior to 2010 Mr. Thibault was Chief Financial Officer and Treasurer of deCODE genetics, Inc. (NASDAQ: DCGN), and a director at PricewaterhouseCoopers LLP. Mr. Thibault is a Certified Public Accountant and received his B.S. in Accountancy from Bentley University.- Lance Thibault，自2015年4月起担任主要财务官兼临时首席财务官，并担任Danforth Advisors, LLC的一个顾问职位；2010年起担任独立顾问；目前是Paratek Pharmaceuticals, Inc.（纳斯达克： PRTK）的财务董事，并且为位于大波斯顿的多家私营制药公司提供运营、财务、战略支持服务。此前，他是deCODE genetics, Inc. （纳斯达克： DCGN）的首席财务官兼财务主管，在PricewaterhouseCoopers LLP担任过多个职位。他获得了Bentley University的会计学学士学位。
- Lance Thibault has served as our Interim Chief Financial Officer since January 2022. Since January 2014 Mr. Thibault has served as managing director of Danforth Advisors, LLC providing operational, financial and strategic services at a number of private and public pharmaceutical and biotechnology companies, including as Interim Chief Financial Officer of Aadi Bioscience, Inc. NASDAQ: AADI from July 2021 to November 2021 as Acting Chief Financial Officer of Pieris Pharmaceuticals, Inc (NASDAQ: PIRS) from February 2017 to April 2018 and as Interim Chief Financial Officer of Proteostasis Therapeutics, Inc. (NASDAQ: PTI) from April 2015 to August 2016. Prior to 2010 Mr. Thibault was Chief Financial Officer and Treasurer of deCODE genetics, Inc. (NASDAQ: DCGN), and a director at PricewaterhouseCoopers LLP. Mr. Thibault is a Certified Public Accountant and received his B.S. in Accountancy from Bentley University.
- Christopher Heery
Christopher Heery自2019年5月起担任我们的首席医疗官。在加入我们之前，Heery博士于2016年10月至2019年4月担任生物技术公司Bavarian NordicA/S的首席医疗官，负责其免疫肿瘤学和传染病组合的临床开发计划。在此之前，他是美国国家癌症研究所（National Cancer Institute&8220；新华保险&8221；）肿瘤免疫学和生物学实验室临床试验小组的副研究员和组长，该研究所是一家美国政府卫生机构，2012年4月至2013年11月和2013年11月至2016年9月，他是更大的努力的一部分，以创造治疗癌症的新免疫疗法。他于2009年加入新华保险医疗肿瘤科，担任医疗肿瘤学研究员，并在泌尿生殖系统恶性肿瘤科担任兼职。Heery博士获得医学肿瘤学和内科的董事会认证。他在杜克大学（Duke University）获得学士学位，在东卡罗莱纳大学布罗迪医学院（East Carolina University Brody School of Medicine）获得医学博士学位，并在伊利诺伊大学芝加哥分校（University of Illinois at Chicago）完成内科住院医师资格。
Christopher Heery has served as our Chief Medical Officer since April 2021. Previously, Dr. Heery, served as Chief Medical Officer of Precision BioSciences, Inc., a genome editing company, from May 2019 to April 2021 where he oversaw the clinical development of one of the first allogeneic CAR-T cell platforms and provided clinical insight into clinical efforts for gene editing therapeutics. Dr. Heery also served as Chief Medical Officer at Bavarian Nordic A/S, a biotechnology company, from October 2016 to April 2019 where he oversaw clinical development programs for its immune-oncology and infectious disease portfolios. Prior to that, he was a Staff Clinician and then an Associate Research Physician and Head of the Clinical Trials Group of the Laboratory of Tumor Immunology and Biology at the National Cancer Institute NCI, a U.S. government health agency, from April 2012 to November 2013 and November 2013 to September 2016 respectively, where he was part of a larger effort to create new immunotherapies for the treatment of cancer. He joined the NCI Medical Oncology Branch as a Medical Oncology Fellow in 2009 and also served as an Adjunct Appointment in the Genitourinary Malignancies Branch. Dr. Heery is board certified in Medical Oncology and Internal Medicine. He received a B.A. from Duke University and a M.D. from East Carolina University Brody School of Medicine, and completed his internal medicine residency at the University of Illinois at Chicago.- Christopher Heery自2019年5月起担任我们的首席医疗官。在加入我们之前，Heery博士于2016年10月至2019年4月担任生物技术公司Bavarian NordicA/S的首席医疗官，负责其免疫肿瘤学和传染病组合的临床开发计划。在此之前，他是美国国家癌症研究所（National Cancer Institute&8220；新华保险&8221；）肿瘤免疫学和生物学实验室临床试验小组的副研究员和组长，该研究所是一家美国政府卫生机构，2012年4月至2013年11月和2013年11月至2016年9月，他是更大的努力的一部分，以创造治疗癌症的新免疫疗法。他于2009年加入新华保险医疗肿瘤科，担任医疗肿瘤学研究员，并在泌尿生殖系统恶性肿瘤科担任兼职。Heery博士获得医学肿瘤学和内科的董事会认证。他在杜克大学（Duke University）获得学士学位，在东卡罗莱纳大学布罗迪医学院（East Carolina University Brody School of Medicine）获得医学博士学位，并在伊利诺伊大学芝加哥分校（University of Illinois at Chicago）完成内科住院医师资格。
- Christopher Heery has served as our Chief Medical Officer since April 2021. Previously, Dr. Heery, served as Chief Medical Officer of Precision BioSciences, Inc., a genome editing company, from May 2019 to April 2021 where he oversaw the clinical development of one of the first allogeneic CAR-T cell platforms and provided clinical insight into clinical efforts for gene editing therapeutics. Dr. Heery also served as Chief Medical Officer at Bavarian Nordic A/S, a biotechnology company, from October 2016 to April 2019 where he oversaw clinical development programs for its immune-oncology and infectious disease portfolios. Prior to that, he was a Staff Clinician and then an Associate Research Physician and Head of the Clinical Trials Group of the Laboratory of Tumor Immunology and Biology at the National Cancer Institute NCI, a U.S. government health agency, from April 2012 to November 2013 and November 2013 to September 2016 respectively, where he was part of a larger effort to create new immunotherapies for the treatment of cancer. He joined the NCI Medical Oncology Branch as a Medical Oncology Fellow in 2009 and also served as an Adjunct Appointment in the Genitourinary Malignancies Branch. Dr. Heery is board certified in Medical Oncology and Internal Medicine. He received a B.A. from Duke University and a M.D. from East Carolina University Brody School of Medicine, and completed his internal medicine residency at the University of Illinois at Chicago.